Citigroup’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Citigroup’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13,000	Closed	-$117K	–	7564
2016 Q3	$117K	Sell	13,000 -3,400	-21%	-$24.2K	﹤0.01%	5100
2016 Q2	$88K	Buy	16,400 +7,200	+78%	+$36.9K	﹤0.01%	5188
2016 Q1	$42K	Sell	9,200 -37,300	-80%	-$150K	﹤0.01%	6201
2015 Q4	$242K	Sell	46,500 -40,500	-47%	-$235K	﹤0.01%	4562
2015 Q3	$526K	Buy	87,000 +18,900	+28%	+$232K	﹤0.01%	3694
2015 Q2	$1.07M	Buy	68,100 +50,700	+291%	+$616K	﹤0.01%	3105
2015 Q1	$189K	Buy	+17,400	New	+$178K	﹤0.01%	4582

Citigroup's RPTP Position: Q4 2016 in Review

Citigroup sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 51,137 shares — an estimated $459K sold.

Citigroup first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $731K in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

Citigroup reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
Citigroup sold 51,137 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $459K.
Citigroup first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
Citigroup's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $731K in Q2 2015.
0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.